• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乙型肝炎消除计划制定与实施中的挑战

Challenges in Formulation and Implementation of Hepatitis B Elimination Programs.

作者信息

Abbas Zaigham, Abbas Minaam

机构信息

Gastroenterology and Hepatology, Dr. Ziauddin University Hospital, Karachi, PAK.

Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, GBR.

出版信息

Cureus. 2021 Apr 24;13(4):e14657. doi: 10.7759/cureus.14657.

DOI:10.7759/cureus.14657
PMID:33907651
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8065944/
Abstract

Nearly 257 million individuals have contracted hepatitis B infection around the world. However, only 10% of them know about their illness. Mother to child transmission, nosocomial spread, and sexual transmission are the major etiological factors. Finding the missing millions is a global issue. Hepatitis B care is more difficult compared to hepatitis C as not all patients require treatment and the selection of patients is not straightforward. To eliminate hepatitis B infection, the program should screen pregnant women and start antiviral therapy from the 28th week of pregnancy if hepatitis B virus (HBV) DNA≥ 200,000 IU/mL or hepatitis B e-antigen (HBeAg) reactive. Prevention of perinatal infection, birth dose and neonatal vaccination, post-vaccination monitoring of high-risk groups, catch-up vaccination, and registration of the carriers should be an integral part of the program. Continuum of care is important when planning the elimination program from addressing the risk factors, testing, and referral for treatment. The program should integrate test and treat hepatitis services with existing local health care services. There is a need to create the right environment, raise awareness, remove stigma, and increase screening of those at risk and manage those who require treatment. A national policy should be prepared for capacity building, fund allocation, and implementation strategies. Micro-elimination strategies should boost national elimination effects. Guidelines to diagnose and treat patients with hepatitis B should be simplified. Surveillance should be done to monitor progress, and determine the impact of the elimination program on incidence and mortality, and services.

摘要

全球约有2.57亿人感染了乙型肝炎病毒。然而,其中只有10%的人知晓自己患病。母婴传播、医院内传播和性传播是主要病因。找到数百万未知感染者是一个全球性问题。与丙型肝炎相比,乙型肝炎的治疗更为困难,因为并非所有患者都需要治疗,而且患者的选择并不简单。为消除乙型肝炎感染,该项目应筛查孕妇,若乙肝病毒(HBV)DNA≥200,000 IU/mL或乙肝e抗原(HBeAg)呈反应性,则应在妊娠第28周开始抗病毒治疗。预防围产期感染、出生时接种疫苗和新生儿接种、对高危人群进行接种后监测、补种疫苗以及对携带者进行登记应成为该项目的组成部分。在规划消除项目时,从解决风险因素、检测和转诊治疗等方面来看,持续护理至关重要。该项目应将乙肝检测和治疗服务与现有的当地医疗服务相结合。需要营造合适的环境,提高认识,消除污名化,增加对高危人群的筛查,并对需要治疗的人进行管理。应制定一项关于能力建设、资金分配和实施战略的国家政策。微观消除战略应提高国家消除效果。应简化乙肝患者诊断和治疗指南。应开展监测以监测进展情况,并确定消除项目对发病率、死亡率及服务的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece7/8065944/b9531e0bd190/cureus-0013-00000014657-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece7/8065944/b9531e0bd190/cureus-0013-00000014657-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece7/8065944/b9531e0bd190/cureus-0013-00000014657-i01.jpg

相似文献

1
Challenges in Formulation and Implementation of Hepatitis B Elimination Programs.乙型肝炎消除计划制定与实施中的挑战
Cureus. 2021 Apr 24;13(4):e14657. doi: 10.7759/cureus.14657.
2
[Clinical study on blocking mother-to-child transmission of hepatitis B virus with high viral load and HBeAg positivity during pregnancy in Guizhou province].[贵州省孕期高病毒载量及HBeAg阳性乙型肝炎病毒母婴传播阻断的临床研究]
Zhonghua Gan Zang Bing Za Zhi. 2018 Dec 20;26(12):945-950. doi: 10.3760/cma.j.issn.1007-3418.2018.12.013.
3
Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis.HBeAg 用于识别有将乙型肝炎病毒传播给新生儿风险的孕妇的准确性:系统评价和荟萃分析。
Lancet Infect Dis. 2021 Jan;21(1):85-96. doi: 10.1016/S1473-3099(20)30593-4. Epub 2020 Aug 14.
4
[Identification of risk factors related to the failure of immunization to interrupt hepatitis B virus perinatal transmission].[与免疫接种未能阻断乙型肝炎病毒围产期传播相关的危险因素的识别]
Zhonghua Gan Zang Bing Za Zhi. 2013 Feb;21(2):105-10. doi: 10.3760/cma.j.issn.1007-3418.2013.02.008.
5
Hepatitis elimination by 2030: Progress and challenges.2030 年消除肝炎:进展与挑战。
World J Gastroenterol. 2018 Nov 28;24(44):4959-4961. doi: 10.3748/wjg.v24.i44.4959.
6
Perinatal transmission in infants of mothers with chronic hepatitis B in California.加利福尼亚州慢性乙型肝炎母亲所生婴儿的围产期传播情况。
World J Gastroenterol. 2017 Jul 21;23(27):4942-4949. doi: 10.3748/wjg.v23.i27.4942.
7
Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.预防乙型肝炎病毒母婴传播:一项III期、安慰剂对照、双盲、随机临床试验,旨在评估替诺福韦酯短期疗程对乙型肝炎病毒e抗原阳性女性的疗效和安全性。
BMC Infect Dis. 2016 Aug 9;16:393. doi: 10.1186/s12879-016-1734-5.
8
Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience.消除乙型肝炎病毒母婴传播:35年的经验
Pediatr Gastroenterol Hepatol Nutr. 2020 Jul;23(4):311-318. doi: 10.5223/pghn.2020.23.4.311. Epub 2020 Jul 3.
9
#38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission.#38:孕期乙型肝炎的筛查、治疗及垂直传播的预防
Am J Obstet Gynecol. 2016 Jan;214(1):6-14. doi: 10.1016/j.ajog.2015.09.100. Epub 2015 Oct 8.
10
Hepatitis B e Antigen (HBeAg) Rapid Test and Alanine Aminotransferase Level-Based Algorithm to Identify Pregnant Women at Risk of HBV Mother-to-Child Transmission: The ANRS 12345 TA PROHM Study.乙肝 e 抗原(HBeAg)快速检测和基于丙氨酸氨基转移酶水平的算法识别乙型肝炎病毒母婴传播高危孕妇:ANRS 12345 TA PROHM 研究。
Clin Infect Dis. 2020 Dec 17;71(10):e587-e593. doi: 10.1093/cid/ciaa282.

引用本文的文献

1
Prevalence of hepatitis B virus infection and treatment eligibility in Lesotho, Southern Africa: a population-based cross-sectional study with case-based follow-up.南非莱索托的乙肝病毒感染患病率及治疗资格:一项基于人群的横断面研究及病例随访研究
BMJ Public Health. 2024 Nov 29;2(2):e001195. doi: 10.1136/bmjph-2024-001195. eCollection 2024 Dec.
2
Increasing Prevalence of Occult HBV Infection in Adults Vaccinated Against Hepatitis B at Birth.出生时接种乙肝疫苗的成年人中隐匿性乙肝病毒感染患病率上升。
Vaccines (Basel). 2025 Feb 12;13(2):174. doi: 10.3390/vaccines13020174.
3
Identifying Expert Opinions on the Challenges and Barriers Faced in Implementing Iraq's National Plan for Controlling Hepatitis B.

本文引用的文献

1
The case for simplifying and using absolute targets for viral hepatitis elimination goals.简化并使用绝对目标来实现病毒性肝炎消除目标的理由。
J Viral Hepat. 2021 Jan;28(1):12-19. doi: 10.1111/jvh.13412. Epub 2020 Nov 4.
2
The impact of COVID-19 on hepatitis elimination.2019冠状病毒病对消除肝炎的影响。
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):792-794. doi: 10.1016/S2468-1253(20)30238-7. Epub 2020 Jul 27.
3
Securing sustainable funding for viral hepatitis elimination plans.为消除病毒性肝炎计划确保可持续资金。
识别关于伊拉克控制乙型肝炎国家计划实施过程中所面临挑战和障碍的专家意见。
Cureus. 2024 Jun 21;16(6):e62814. doi: 10.7759/cureus.62814. eCollection 2024 Jun.
4
Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030.全球乙肝疫苗接种的视角:挑战、成就以及2030年实现消除的道路
Vaccines (Basel). 2024 Mar 9;12(3):288. doi: 10.3390/vaccines12030288.
5
A nationwide cross-sectional review of in-hospital hepatitis B virus testing and disease burden estimation in Ghana, 2016 - 2021.加纳 2016-2021 年全国性横断面研究,评估住院乙型肝炎病毒检测及疾病负担。
BMC Public Health. 2022 Nov 23;22(1):2149. doi: 10.1186/s12889-022-14618-3.
Liver Int. 2020 Feb;40(2):260-270. doi: 10.1111/liv.14282. Epub 2019 Dec 5.
4
Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.国家层面消除病毒性肝炎的创新策略:一个国家案例系列。
Liver Int. 2019 Oct;39(10):1818-1836. doi: 10.1111/liv.14222. Epub 2019 Sep 4.
5
Global Elimination of Chronic Hepatitis.全球消除慢性肝炎
N Engl J Med. 2019 May 23;380(21):2041-2050. doi: 10.1056/NEJMra1810477.
6
Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States.美国6种高危人群中乙型肝炎病毒感染筛查、治疗或疫苗接种的成本效益
Open Forum Infect Dis. 2018 Dec 26;6(1):ofy353. doi: 10.1093/ofid/ofy353. eCollection 2019 Jan.
7
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.加速消除病毒性肝炎:柳叶刀胃肠病学和肝脏病学委员会报告
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184. doi: 10.1016/S2468-1253(18)30270-X.
8
Hepatitis elimination by 2030: Progress and challenges.2030 年消除肝炎:进展与挑战。
World J Gastroenterol. 2018 Nov 28;24(44):4959-4961. doi: 10.3748/wjg.v24.i44.4959.
9
Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial.基层医疗中慢性病毒性肝炎的病例发现和治疗(HepFREE):一项整群随机对照试验。
Lancet Gastroenterol Hepatol. 2019 Jan;4(1):32-44. doi: 10.1016/S2468-1253(18)30318-2. Epub 2018 Nov 24.
10
An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.埃及消除丙型肝炎感染的教育、检测和治疗方案:基于社区的示范项目。
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):778-789. doi: 10.1016/S2468-1253(18)30139-0. Epub 2018 Jul 18.